Science Explorer Back to mapMap
Institution · Hansoh Pharma (China)

Most cited papers from Hansoh Pharma (China)

What are the most cited papers from Hansoh Pharma (China)?

The most cited paper from Hansoh Pharma (China) is "AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations" (Shun Lü et al., 2022), with 302 citations. Next come "Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial" (152) and "MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy" (66).

Showing 50 of 61 papers. Every paper with more than 4 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations Shun Lü et al. · Journal of Clinical Oncology Open access 17 May 2022 302
2 Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial Shun Lü et al. · Journal of Thoracic Oncology Open access 19 Nov 2021 152
3 MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy Yan Wei, Sha Song, Nianxiu Duan et al. · Advanced Science Open access 10 Jul 2020 66
4 Development of an UPLC–MS/MS method for simultaneous quantitation of 11 d -amino acids in different regions of rat brain: Application to a study on the associations of d -amino acid concentration changes and Alzheimer’s disease Zhe Li, Yuping Xing, Xingjie Guo et al. · Journal of Chromatography B 11 May 2017 44
5 The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient Yihui Deng, Yanzhi Song, Zhenjun Huang et al. · International Journal of Nanomedicine Open access Aug 2014 39
6 Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS) Shun Lü et al. · 癌症:英文版 Open access 17 Jul 2024 30
7 Characterization, Large-Scale HSCCC Separation and Neuroprotective Effects of Polyphenols from Moringa oleifera Leaves Qian Gao, Zongmin Wei, Yun Liu et al. · Molecules Open access 20 Jan 2022 30
8 A Concise and Efficient Synthesis of Dapagliflozin Jun Yu, Ying Cao, Haizhou Yu et al. · Organic Process Research & Development 27 Jun 2019 30
9 Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates Aifeng Lyu, Lei Fang, Shaohua Gou · European Journal of Medicinal Chemistry Open access 5 Oct 2014 29
10 Enzyme‐Activated Prodrug‐Based Smart Liposomes Specifically Enhance Tumor Hemoperfusion with Efficient Drug Delivery to Pancreatic Cancer Cells and Stellate Cells Nianxiu Duan, Junjun Li, Sha Song et al. · Advanced Functional Materials 11 Aug 2021 28
11 Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial Hongyu Cai, Qianqian Chen, Yale Duan et al. · Frontiers in Endocrinology Open access 26 Jan 2023 24
12 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Zhihong Liu et al. · Journal of Clinical and Translational Hepatology Open access Nov 2022 24
13 Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors Ling Huang, Wenjun Shan, Qi Zhou et al. · Bioorganic & Medicinal Chemistry Letters Open access 21 Nov 2013 22
14 381O First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors Jing Wu, Jiawen Zhang, Han Li et al. · Annals of Oncology Open access Oct 2023 19
15 Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies Andrew B. Dippel et al. · mAbs Open access 8 Dec 2022 19
16 HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial Jianchun Duan et al. · Cancer Cell Open access 5 Mar 2026 18
17 The endorsement of general and artificial intelligence reporting guidelines in radiological journals: a meta-research study Jingyu Zhong, Yue Xing, Junjie Anderson Lu et al. · BMC Medical Research Methodology Open access 13 Dec 2023 18
18 Development and Validation of a Stability-Indicating HPLC Method for Determination of Voriconazole and Its Related Substances Peng Gu, You Li · Journal of Chromatographic Science Aug 2009 18
19 Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial Ping Zhang et al. · EClinicalMedicine Open access 28 Oct 2023 17
20 Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway Shi Chen, Cong Wang, Zhiwen Fu et al. · Pharmacological Research Open access Feb 2024 16
21 Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice Yu Zhang, Yufeng Li, Junjun Zhao et al. · Frontiers in Pharmacology Open access 6 Dec 2021 14
22 Synthesis and pharmacological evaluation of 2,3‐diphenyl acrylonitriles‐bearing halogen as selective anticancer agents Jiajun Li, Jun Ma, Yabing Xin et al. · Chemical Biology & Drug Design 8 Mar 2018 14
23 EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation Yang Chen, Wang Youyou, Zhao Lujun et al. · Cancer Biology and Medicine Open access 2018 14
24 Novel anilinopyrimidine derivatives as potential EGFRT790M/C797S Inhibitors: Design, Synthesis, biological activity study Yanliang Guo, Biao Gao, Peng Gao et al. · Bioorganic & Medicinal Chemistry Open access 5 Jul 2022 13
25 Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations Chen Shi, Cong Zhang, Zhiwen Fu et al. · Acta Pharmaceutica Sinica B Open access 10 Mar 2023 12
26 In situ PEGylation of recombinant hirudin on an anion exchange chromatography column Xudong Wang, Xueqin Li, Jun Zhao et al. · Process Biochemistry 3 Feb 2017 12
27 Nbs1‐mediated DNA damage repair pathway regulates haematopoietic stem cell development and embryonic haematopoiesis Yu Chen, Jie Sun, Zhenyu Ju et al. · Cell Proliferation Open access 14 Feb 2021 10
28 Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial Liang Zhang, XiQin Zhang, Lin Wu et al. · The Lancet Oncology 12 Jan 2026 9
29 Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway Chen Shi, Qilin Zhang, Yufeng Li et al. · BMC Cardiovascular Disorders Open access 18 Dec 2024 9
30 The policies on the use of large language models in radiological journals are lacking: a meta-research study Jingyu Zhong, Yue Xing, Yangfan Hu et al. · Insights into Imaging Open access Aug 2024 9
31 Development of a Modified Process for the Kilogram-Scale Synthesis of c-Met/ALK Inhibitor HS-10168 Jun Yu, Jinjia Wang · Organic Process Research & Development 6 Jan 2017 9
32 Black-start Scheme for China Southern Power Grid Zhang Zu · Dianli xitong zidonghua 2006 9
33 First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial Jong-Mu Sun, Y. Chao, Sung-Bae Kim et al. · The Lancet Oncology Open access 23 Dec 2025 8
34 HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer Jianhua Zhan et al. · Journal of Translational Medicine Open access 4 Jun 2025 8
35 ECM characterization and 3D bioprinted models of NSCLC for investigating stiffness-dependent tumor behavior and drug response Shiwei Xu, Xin Shun Sun, Yexin Gu et al. · Materials Today Bio Open access May 2025 8
36 Overview of preclinical and phase II clinical studies on Pegmolesatide’s long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction Xiaoying Ma, Zhen Li, Lu Zhang et al. · Journal of Translational Medicine Open access 2 Feb 2025 8
37 Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial Xiaoyan Liu, Rui Zhang, Rong Li et al. · Antimicrobial Agents and Chemotherapy Open access 16 Nov 2023 8
38 Kinetic Optimization and Scale-Up of Site-Specific Thiol-PEGylation of Loxenatide from Laboratory to Pilot Scale Xudong Wang, Ning-Ning Wei, Shuchang Wang et al. · Industrial & Engineering Chemistry Research 15 Oct 2018 8
39 Synthesis and characterisation of (Z)-styrylbenzene derivatives as potential selective anticancer agents Yabing Xin, Jiajun Li, Hongjian Zhang et al. · Journal of Enzyme Inhibition and Medicinal Chemistry Open access 2018 8
40 Preparation of tenofovir amibufenamide fumarate spherical particles to improve tableting performance and sticking propensity by designing a spherical crystallization process Yanbo Liu, Xiaolei Wang, Chenyang Zhao et al. · International Journal of Pharmaceutics 19 Sep 2024 7
41 Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer Xiaojuan Zhang, Mina Zhang, Xinyang Du et al. · Frontiers in Pharmacology Open access 9 Apr 2024 7
42 Synthesis of Monofluorocyclohexene via Photocatalytic Defluorinative [4+2] Annulation of gem‐Difluoroalkenes with Unactivated Alkenes Guangxu Zhang, Dong‐Sheng Li, Fei Xue et al. · Advanced Synthesis & Catalysis Nov 2023 7
43 Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report Zhiquan Qin, Hang Zhang, Peiyuan Yan et al. · Journal of Thoracic Disease Open access Jul 2023 7
44 Synthesis of α-allenic aldehydes/ketones from homopropargylic alcohols using a visible-light irradiation system Dongfang Jiang, Xingxing Zeng, De‐Feng Li et al. · Organic & Biomolecular Chemistry 2023 7
45 Optimum conditions of ultrasound‐assisted extraction and pharmacological activity study for phenolic compounds of the alga Chondrus ocellatus Yuexia Zhu, Weiqi Chen, Li Kong et al. · Journal of Food Processing and Preservation 21 Jan 2022 7
46 Improvement of the key flavour compounds of fermented garlic by fermentation process optimization Leng Yun-wei, Huang Shuangshuang, Bing Chen · AFRICAN JOURNAL OF BIOTECHNOLOGY Open access 31 Oct 2020 7
47 Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies Changan Sun, Lei Fang, Xiaobing Zhang et al. · Bioorganic & Medicinal Chemistry Open access 10 Apr 2019 7
48 Stereoselective N-glycosylation with N4-acyl cytosines and efficient synthesis of gemcitabine Tongchao Liu, Jiadeng Tang, Jianpeng Liang et al. · Tetrahedron 17 Jan 2019 7
49 A chiral high-performance liquid chromatography–tandem mass spectrometry method for the stereospecific determination of morinidazole in human plasma Kan Zhong, Zhiwei Gao, Qin Li et al. · Journal of Chromatography B 2 May 2014 7
50 Stimulation of nitric oxide production contributes to the antiplatelet and antithrombotic effect of new peptide pENW (pGlu-Asn-Trp) Yamin Liu, Wenjing Luo, Huan Yang et al. · Thrombosis Research 21 May 2015 7

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.